Corindus Vascular Robotics

Microbot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series

Retrieved on: 
Tuesday, January 31, 2023
Columbia University Irving Medical Center, NewYork-Presbyterian Hudson Valley Hospital, Safety, Navigation, Vision Guided Robotic Systems, Health, FIH, PCI, Web conferencing, Physician, Patient, Q&A, Public, Time-invariant system, Interventional cardiology, Clinical trial, Siemens Healthineers, Faculty, Cardiology, Corindus Vascular Robotics, Associate, Medical device, Medicine

HINGHAM, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, announced the next episode of its highly successful “Access-Ability Live by MBOT” webinar, which is intended for all stakeholders interested in the endovascular robotic space and will be held on Wednesday, February 8, 2023, at 1:00pm ET. It will be hosted by the Company’s Chief Medical Officer, Dr. Eyal Morag.

Key Points: 
  • It will be hosted by the Company’s Chief Medical Officer, Dr. Eyal Morag.
  • He is also a faculty member at the Cardiovascular Research Foundation in New York.
  • Dr. Weisz, who has a particular interest in current and innovative technologies in cardiovascular medicine, is an early adopter of robotic-enhanced coronary interventions, as well as navigation and positioning technologies.
  • The “Access-Ability Live by MBOT” webinar series focuses on key topics in the healthcare and endovascular space.

The Worldwide Robotic Vascular Catheter System Industry is Expected to Reach $541.1 Million in 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 23, 2022
Medical Devices, Health, Acquisition, Stereotaxis, COVID-19, Sensei, Magele Mauiliu Magele, Corindus Vascular Robotics, Johnson & Johnson, 3D printing

The global robotic vascular catheter system market experienced a surge in the number of procedures performed in 2021.

Key Points: 
  • The global robotic vascular catheter system market experienced a surge in the number of procedures performed in 2021.
  • In 2020, the market had actually seen a reduction in procedure volume as a result of the global COVID-19 pandemic.
  • Overall, within the global robotic vascular catheter system market there are three dominant competitors: Auris Health, Stereotaxis, and Corindus Vascular Robotics.
  • Auris Health, a Johnson & Johnson company, led the global robotic vascular catheter system market in 2021 through its acquisition of Hansen Medicala a few years prior.

Siemens Healthineers to demonstrate the remote capabilities of Corindus CorPath GRX Robotic System using Mentice VIST ® Simulator

Retrieved on: 
Wednesday, November 9, 2022
Acquisition, Neurovascular bundle, Patient, China International Import Expo, Siemens Healthineers, Corindus Vascular Robotics, Policy by press release, Group, Partnership, Solution, Molecular medicine, CEO, Medical imaging

GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ --Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the remote capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIST Virtual Patient simulator.

Key Points: 
  • GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ --Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the remote capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIST Virtual Patient simulator.
  • This year's China International Import Expo (CIIE 2022) will be the first event to showcase the CorPath GRX Robotic System and Mentice VIST Virtual Patient integration.
  • The VIST Virtual Patient simulator enables Siemens Healthineers to demonstrate the unique capabilities of the CorPath GRX Robotic System effectively and realistically.The integration facilitates the training and onboarding of interventionalists and their teams, to support the transition and utilization of robotic-assisted vascular interventions.
  • "Following the Press Release from December 27, 2021, and the bundling of Mentice VIST simulators with Corindus CorPath GRX Robotic system in China, the demonstration at CIIE is another milestone in our partnership with Siemens Healthineers," says Gran Malmberg, CEO and Group President of Mentice.

Siemens Healthineers to demonstrate the remote capabilities of Corindus CorPath GRX Robotic System using Mentice VIST ® Simulator

Retrieved on: 
Wednesday, November 9, 2022
Acquisition, Neurovascular bundle, Patient, China International Import Expo, Siemens Healthineers, Corindus Vascular Robotics, Policy by press release, Group, Partnership, Solution, Molecular medicine, CEO, Medical imaging

GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ --Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the remote capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIST Virtual Patient simulator.

Key Points: 
  • GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ --Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the remote capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIST Virtual Patient simulator.
  • This year's China International Import Expo (CIIE 2022) will be the first event to showcase the CorPath GRX Robotic System and Mentice VIST Virtual Patient integration.
  • The VIST Virtual Patient simulator enables Siemens Healthineers to demonstrate the unique capabilities of the CorPath GRX Robotic System effectively and realistically.The integration facilitates the training and onboarding of interventionalists and their teams, to support the transition and utilization of robotic-assisted vascular interventions.
  • "Following the Press Release from December 27, 2021, and the bundling of Mentice VIST simulators with Corindus CorPath GRX Robotic system in China, the demonstration at CIIE is another milestone in our partnership with Siemens Healthineers," says Gran Malmberg, CEO and Group President of Mentice.

Corindus, A Siemens Healthineers Company, Announces Study Results Demonstrating Safety and Effectiveness of CorPath® GRX Neurovascular System

Retrieved on: 
Monday, September 12, 2022
Robotics, Medical Devices, Health, Technology, Surgery, Health Technology, Workflow, Safety, Aneurysm, Modified Rankin Scale, FDA, European Society of Cardiology, CE marking, Thrombosis, Patient, Physician, Dissection, Â, MRS, Doctor of Philosophy, Robotics, Collection, Congress, Multimedia, AI, Pharmaceutical industry, Medical device, Corindus Vascular Robotics, MD

Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.

Key Points: 
  • Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.
  • View the full release here: https://www.businesswire.com/news/home/20220907006221/en/
    CorPath GRX Neurovascular System (Photo: Business Wire)
    The prospective, single-arm, international, multi-center, non-inferiority study is the worlds first trial on robotic-assisted neurovascular aneurysm embolization.
  • Key findings of the study showed:
    The CorPath GRX Neurovascular System demonstrated 94 percent technical success.
  • The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels.

Ganymed Robotics Appoints Michel Therin and Mike Lobinsky on its Board of Directors

Retrieved on: 
Thursday, September 1, 2022
Software, Radiology, Hardware, Data Management, Technology, Medical Devices, Health Technology, Surgery, Cardiology, Biotechnology, Audio, Video, Other Technology, Health, EOS, Wilco, CEO, Technology, Organizational founder, Research, Lists of people executed in the United States, Artificial intelligence, Smith, Robotics, EOS imaging, Judgement, Board, Director, Intelligence, Elective surgery, Corindus Vascular Robotics, Leadership, Maggot therapy, Independent Board for Presbyterian Foreign Missions, BAE Systems Electronic Systems, General surgery, News, Algorithm, Stryker, Siemens Healthineers, Medtronic, Efficiency, Advanced Therapy Medicinal Product, Industry, Acquisition, Ministry of Education (Malaysia), Patient, Management, Medical device, 3D printing, Ganymed, Covidien

Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.

Key Points: 
  • Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.
  • Aside of its role as Chairman of Ganymed, Michel also serves as a Member of the Board of Directors of Tissium, Keranova, SafeHeal, Affluent Medical and Betaglue Technologies.
  • Mike Lobinsky is an accomplished medical technology executive with more than 20 years of experience in the orthopedics and surgical robotics industry.
  • Sophie Cahen, CEO and Cofounder of Ganymed Robotics, said: The arrival of Michel and Mike on our Board is terrific news as we are expanding our technology platform and preparing for commercialization.

Siemens Healthineers and The Ohio State University Wexner Medical Center Announce Strategic Partnership Focused on Personalized Medicine and Increased Access to High Quality Healthcare

Retrieved on: 
Tuesday, June 28, 2022
General Health, Health Technology, Health, Efficiency, EBIT, Health, Artificial intelligence, Patient, Powell, International Training Center for Bankers, Ohio State University Wexner Medical Center, Research, Radiosurgery, Claustrophobia, Intelligence, Radiation therapy, Cancer, Biograph, Goal, Digital pet, The James Cancer Hospital, Ohio State University, Siemens Healthineers, Proton therapy, Digital, Partnership, Corindus Vascular Robotics, Technology, Organization, Machine learning, Medicine, Solution, Pathology, Twitter, Physician, MRI, Thought, Algorithm, Education, Pharmaceutical industry, Medical imaging, Varian

Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed at advancing personalized medicine and improving access to high quality, cost-effective healthcare.

Key Points: 
  • Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed at advancing personalized medicine and improving access to high quality, cost-effective healthcare.
  • Through the five-year strategic partnership, Siemens Healthineers and Varian, a Siemens Healthineers company, will provide comprehensive technology and services that will build on previous successful collaborative projects.
  • One of the nations leading academic health centers, The Ohio State University Wexner Medical Center offers health care services in virtually every specialty and subspecialty in medicine.
  • At Ohio State Wexner Medical Center, were dedicated to improving health in Ohio and across the world through innovation in research, education and patient care.

Corindus, A Siemens Healthineers Company, to Showcase CorPath® GRX Robotic System at EuroPCR 2022

Retrieved on: 
Thursday, May 12, 2022
Science, Cardiology, Research, Health, Medical Devices, Technology, Clinical Trials, Other Technology, Cardiology, CT, PCI, Patient, Jagiellonian University Medical College, Workflow, Automation, CE, Robotics, Research, Institute, FDA, Siemens Healthineers, Constantin, Siemens, Program, Safety, Coronary artery disease, Diagnosis, Medical device, Medical imaging, Corindus Vascular Robotics

Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today that it will showcase the CorPath GRX System, the first and only FDA-cleared and CE marked medical device for robotic-assisted coronary interventions, at EuroPCR 2022 through live cases, scientific presentations, and multiple Siemens Healthineers-sponsored symposia.

Key Points: 
  • Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today that it will showcase the CorPath GRX System, the first and only FDA-cleared and CE marked medical device for robotic-assisted coronary interventions, at EuroPCR 2022 through live cases, scientific presentations, and multiple Siemens Healthineers-sponsored symposia.
  • The course is scheduled to open with a live broadcast of a robotic-assisted PCI case performed at Clinique Pasteur in Toulouse, France, during which the clinical team will utilize a CorPath GRX System.
  • The same day, Siemens Healthineers will host an educational symposium on imaging and robotics, Personalized coronary intervention with CT-guided robotic-assisted PCI.
  • I look forward to sharing my experience with CorPath GRX and the benefits the system has to offer at this years EuroPCR course.

Mentice publishes the company's interim report for the period January-March 2022

Retrieved on: 
Wednesday, April 27, 2022
Neurovascular bundle, COVID-19, Siemens Healthineers, GRX, Software, EBITDA, Hospital, EPS, Depreciation, Revenue stream, Growth, EU, Solution, Corindus Vascular Robotics, SEK, MNTC, Time, Lithium, Financial adviser, Video game, Bookkeeping, Medical device

We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK.

Key Points: 
  • We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK.
  • Mentice (publ) interim report for January-March 2022 will be presented by CEO Gran Malmberg with the possibility to ask questions on April 27, 2022 at 10.00 CET.
  • Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry.
  • The information was submitted for publication, through the agency of the contact person, at 08.30 CET on April 27, 2022.

Mentice publishes the company's interim report for the period January-March 2022

Retrieved on: 
Wednesday, April 27, 2022
Neurovascular bundle, COVID-19, Siemens Healthineers, GRX, Software, EBITDA, Hospital, EPS, Depreciation, Revenue stream, Growth, EU, Solution, Corindus Vascular Robotics, SEK, MNTC, Time, Lithium, Financial adviser, Video game, Bookkeeping, Medical device

We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK.

Key Points: 
  • We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK.
  • Mentice (publ) interim report for January-March 2022 will be presented by CEO Gran Malmberg with the possibility to ask questions on April 27, 2022 at 10.00 CET.
  • Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry.
  • The information was submitted for publication, through the agency of the contact person, at 08.30 CET on April 27, 2022.